AI Drug Discovery's Credibility Problem Predates the Hype Cycle
A cluster of AI drug discovery announcements this week exposed a field where publication volume has outpaced any validated outcome, and the gap is now a structural liability.
A cluster of AI drug discovery announcements this week exposed a field where publication volume has outpaced any validated outcome, and the gap is now a structural liability.
You've read 10 of 10 free stories this month. Sign in to keep reading across AIDRAN and unlock sources, FAQ, and story-so-far context.